Andalib Danandeh, MD
Family Medicine · Fruita, CONPI 1093200123
Payments from drug & device makers
Across 197 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$713
- Lilly USA, LLC$402
- Pfizer$374
- Bayer$342
- AbbVie$298
- AstraZeneca$285
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,895100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $713 |
| Lilly USA, LLC | 21 | $402 |
| Pfizer | 24 | $374 |
| Bayer | 16 | $342 |
| AbbVie | 15 | $298 |
| AstraZeneca | 16 | $285 |
| Otsuka America Pharmaceutical, Inc. | 11 | $181 |
| Myriad Women's Health, Inc. | 1 | $178 |
| Amgen | 9 | $157 |
| Boston Scientific | 3 | $156 |
| Exact Sciences | 5 | $97 |
| Boehringer Ingelheim | 6 | $93 |
| GSK | 6 | $80 |
| Sumitomo Pharma America, Inc. | 4 | $76 |
| Inspire Medical Systems, Inc. | 2 | $61 |
| Novartis | 3 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Astellas Pharma US Inc | 2 | $43 |
| Medtronic | 1 | $37 |
| Nevro Corp. | 2 | $34 |
| Insulet Corporation | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,895 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 175 | $200,025 |
| FarxigaDapagliflozin Propanediol | 210 | $173,140 |
| EliquisApixaban | 129 | $97,461 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $93,492 |
| JardianceEmpagliflozin | 48 | $53,846 |
| MounjaroTirzepatide | 37 | $44,383 |
| JanuviaSitagliptin Phosphate | 30 | $43,860 |
| TrulicityDulaglutide | 23 | $30,573 |
| GemtesaVibegron | 27 | $30,343 |
| RybelsusSemaglutide | 23 | $28,417 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $28,338 |
| VraylarCariprazine Hcl | 20 | $27,703 |
| EntrestoSacubitril/Valsartan | 20 | $24,596 |
| KerendiaFinerenone | 26 | $23,602 |
| QuliptaAtogepant | 15 | $22,844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $713 | $228,442198 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $285 | $201,478251 claims |
| PfizerEliquis | $374 | $97,461129 claims |
| GSKTrelegy Ellipta | $80 | $93,492124 claims |
| Lilly USA, LLCMounjaro, Trulicity | $402 | $74,95660 claims |
| AbbVieVraylar, Qulipta, Ubrelvy, Lumigan | $298 | $72,08180 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $93 | $61,05863 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $76 | $30,34327 claims |
| NovartisEntresto | $45 | $24,59620 claims |
| BayerKerendia | $342 | $23,60226 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $181 | $21,56311 claims |
| Johnson & JohnsonXarelto | $20 | $19,32728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Fruita
- Kurtis HolmesFruita$56K
- Vanessa McClellanFruita$16K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Timothy ColanderAurora$3.1M
- Mia ScottDenver$993K
- Matthew LewisAurora$960K
- Ethan LazarusDenver$688K
- Patrick BarryFraser$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.